Lead Product(s) : Minzasolmin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Minzasolmin Proof-of-Concept Study Shapes UCB Parkinson’s Research Program Next Steps
Details : UCB0599 (minzasolmin), an investigational, oral small molecule, alpha-synuclein misfolding inhibitor, being developed in partnership with Novartis for Parkinson’s disease failed to meet endpoints.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 16, 2024
Lead Product(s) : Minzasolmin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable